Nature Medicine, Published online: 13 October 2026; doi:10.1038/s41591-026-04714-x
A secondary analysis of trial data shows that both host antibodies and infused antibodies against HIV help to delay viral rebound after interruption of antiretroviral therapy (ART), which could inform approaches to durable, ART-free HIV control.
